Key result
Atrial antitachycardia pacing successfully converted 73%, 96%, and 97% of intra-atrial reentrant tachycardia episodes in three patients with varying complex congenital heart disease anatomies.
Why the study?
Does atrial antitachycardia pacing improve the conversion of intra-atrial reentrant tachycardia in patients with complex congenital heart disease?
Case Report (n=3)
No
Does atrial antitachycardia pacing improve the conversion of intra-atrial reentrant tachycardia in patients with complex congenital heart disease?
Atrial antitachycardia pacing can be highly effective for terminating intra-atrial reentrant tachycardia in patients with complex congenital heart disease, though efficacy and detection challenges vary by individual anatomy.
Among the congenital heart disease (CHD) population, intra-atrial reentrant tachycardia (IART) is a common sequela resulting from anatomical anomalies and surgical scars that significantly increases morbidity and mortality. Atrial antitachycardia pacing (ATP) delivered by atrial antitachycardia devices (ATDs) has been used to treat IART in the CHD population. However, there remains limited data on the safety and efficacy of ATP, as well as on comparisons of its effects amongst different CHD subtypes. The purpose of the current study is to describe the clinical history and ATP efficacy in three patients with unique forms of complex CHD. During this study, a single-center review of three patients with ATDs was performed. One patient with each of the following CHD anomalies was selected for inclusion: systemic left ventricle, systemic right ventricle, and single ventricle. Data collected included ATP success rates, medications in use, direct current (DC) cardioversions, and any complications related to the ATDs. Study findings revealed the patient with a systemic left ventricle had an ATD implanted for approximately 9.5 years, with 695 of 956 (73%) episodes successfully converted. Unsuccessfully treated episodes were generally asymptomatic and self-terminating in this patient. The patient with a systemic right ventricle had an ATD implanted for approximately 16 years, with 333 of 348 (96%) episodes being successfully converted. The patient with a single ventricle had an ATD implanted for approximately 12.5 years, with 404 of 416 (97%) episodes successfully converted. The patients with biventricular physiology were able to forgo DC cardioversion after receiving their ATDs. However, due to medical noncompliance as well as multiple episodes of IART, which presented with 1:1 conduction or low rates, the single-ventricle patient still required DC cardioversions post-ATD implantation. In conclusion, this study's findings demonstrate that, while ATP can be effective in a wide variety of CHDs, experiences can vary based on individual arrhythmia substrates, cardiac anatomy, and medical compliance. Additionally, challenges remain in IART detection in patients with especially complex CHD anatomies.
No takes yet. Share an insight, caveat, or question.
Kramer et al. (2018) conducted a case report in Complex congenital heart disease with intra-atrial reentrant tachycardia (n=3). Atrial antitachycardia pacing (ATP) was evaluated on Successful conversion of intra-atrial reentrant tachycardia episodes. Atrial antitachycardia pacing successfully converted 73%, 96%, and 97% of intra-atrial reentrant tachycardia episodes in three patients with varying complex congenital heart disease anatomies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: